Preclinical evidence shows cannabinoids can inhibit skin cancer growth through multiple mechanisms, but clinical translation remains limited by lack of human trials.
Dermatology researchers, oncologists, and people interested in cannabinoids and cancer research.
Cannabinoids target multiple skin cancer pathways simultaneously
What the researchers found
Phytocannabinoids, endocannabinoids, and synthetic cannabinoids demonstrated antitumor activity against melanoma and non-melanoma skin cancers in preclinical models by inhibiting proliferation, angiogenesis, invasion, and metastasis while inducing apoptosis and autophagy. CBD-based topical formulations designed for skin penetration show particular promise.
Why it matters
Skin cancer incidence is rising globally, and current treatments have limitations. Cannabinoids represent a pharmacologically distinct approach that targets multiple cancer pathways simultaneously, and topical delivery could potentially minimize systemic side effects.
The numbers in context
Cannabinoids demonstrated antitumor activity through inhibition of tumor proliferation, angiogenesis, invasion, and metastasis. Both receptor-dependent (CB1, CB2) and receptor-independent mechanisms were identified. CBD topical formulations showed enhanced skin penetration.
How the study worked
Comprehensive review synthesizing the most recent preclinical evidence on cannabinoids in melanoma and non-melanoma skin cancers, examining both receptor-dependent and receptor-independent mechanisms plus emerging delivery strategies.
What this study cannot tell us
Almost entirely based on preclinical data. No large skin-cancer-specific clinical trials exist. Variability in cannabinoid preparations, dosing, and formulations makes comparison across studies difficult.
How to read the evidence
Comprehensive review in a respected journal synthesizing substantial preclinical evidence, but virtually no human clinical data exists.
When this study was published
2026 review of preclinical evidence.
The bigger picture
While cannabinoid-skin cancer research is encouraging at the preclinical level, it faces the same translational gap as much cannabinoid oncology research. The development of topical CBD delivery systems could accelerate clinical testing by offering a localized treatment approach.
Questions still open
- Could topical cannabinoid formulations be effective as adjuvant therapy for early-stage skin cancers? What cannabinoid concentrations are achievable in skin tumors with topical application?
Common questions
Can cannabinoids treat skin cancer?
Why are topical formulations important?
Read the original research
Cannabinoids and skin cancer: Mechanistic insights, therapeutic potential, and translational perspectives.
Experimental and molecular pathology, 145, 105027
Citation
Pareek, Ashutosh; Gupta, Rashi; Pareek, Aaushi; Wilkerson, Jenny; McMahon, Lance R; Sethi, Gautam; Chuturgoon, Anil. (2026). Cannabinoids and skin cancer: Mechanistic insights, therapeutic potential, and translational perspectives.. Experimental and molecular pathology, 145, 105027. https://doi.org/10.1016/j.yexmp.2026.105027
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk